Skip to main content

Propanc Biopharma, Inc.

corporate_fare Company Profile

Propanc Biopharma, Inc.

Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. The company has a research and collaboration agreement with the University of Jaén, to undertakes the research activities for the POP1 Program and the University of Granada to develop a synthetic recombinant version of PRP. Propanc Biopharma, Inc. was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. The company was incorporated in 2007 and is based in Camberwell, Australia.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed PPCB - Latest Insights

PPCB
Apr 10, 2026, 5:29 PM EDT
Filing Type: S-1
Importance Score:
9
PPCB
Mar 19, 2026, 8:07 PM EDT
Filing Type: PRE 14C
Importance Score:
9
PPCB
Mar 19, 2026, 5:30 PM EDT
Filing Type: PRE 14A
Importance Score:
9
PPCB
Mar 10, 2026, 8:45 AM EDT
Source: GlobeNewswire
Importance Score:
8
PPCB
Mar 06, 2026, 5:22 PM EST
Filing Type: 424B3
Importance Score:
9
PPCB
Mar 03, 2026, 8:48 AM EST
Source: Reuters
Importance Score:
8
PPCB
Feb 26, 2026, 5:19 PM EST
Filing Type: 8-K
Importance Score:
7
PPCB
Feb 17, 2026, 2:54 PM EST
Filing Type: 10-Q
Importance Score:
9
PPCB
Feb 02, 2026, 5:29 PM EST
Filing Type: S-1
Importance Score:
9
PPCB
Jan 29, 2026, 9:33 PM EST
Filing Type: 424B3
Importance Score:
8
PPCB
Jan 07, 2026, 5:00 PM EST
Filing Type: 8-K
Importance Score:
9